Premature ovarian insufficiency/failure (POI/POF) is a significant issue for women of reproductive age. Anti-Müllerian hormone (AMH) is a potential biomarker of ovarian reserve, but its clinical value in diagnosing and predicting POI/POF remains unclear. This study aimed to analyze the correlation between AMH and basal follicle-stimulating hormone (FSH) levels in women aged 18 to 40 and evaluate AMH's predictive value for POI/POF.
Methods
A total of 21,143 participants aged 18-40 who visited the gynecology department or underwent physical examinations at the International Peace Maternity and Child Health Hospital in Shanghai, China, from July 2016 to June 2021 were enrolled. Demographic information and laboratory test results were collected, including age, FSH, AMH, E2 and test dates. Participants were grouped by FSH and AMH levels, and subgroup analyses were performed to investigate the relationship between these hormones and age. The AMH level associated with POI risk was evaluated using restricted cubic splines (RCS) and logistic regression. Clinical benefit was assessed by decision curve analysis (DCA).
Results
Participants with higher FSH levels had significantly lower median AMH levels and vice versa(p<0.001). At AMH ≥ 0.5 ng/mL, FSH levels were normal or slightly elevated with age. At AMH level below 0.5ng/ml,basal FSH increased significantly with age. At FSH <10 IU/L, AMH levels show a trend of rising and then decreasing with age, reaching a peak at approximately 25 years old and gradually decreasing with age. At FSH ≥10 IU/L, AMH levels show a gradual downward trend with age, and at FSH >40 IU/L, AMH levels remain very low to undetectable values. The RCS showed that the risk of POI/POF in the overall population sharply increased until serum AMH reached a low level (below 0.5ng/ml). DCA showed that a low AMH level had good clinical diagnostic utility in predicting POI/POF.
Conclusion
Our analysis of a large dataset suggests that serum AMH levels are inversely correlated with FSH levels and that AMH is a good predictor of POI until it drops to a low level.
PMID 39629049 39629049 DOI 10.3389/fendo.2024.1454802 10.3389/fendo.2024.1454802
Cite this article
Huang, Y., Kuang, X., Jiangzhou, H., Li, M., Yang, D., & Lai, D. (2024). Using anti-Müllerian hormone to predict premature ovarian insufficiency: a retrospective cross-sectional study. *Frontiers in endocrinology*, *15*, 1454802. https://doi.org/10.3389/fendo.2024.1454802
Huang Y, Kuang X, Jiangzhou H, Li M, Yang D, Lai D. Using anti-Müllerian hormone to predict premature ovarian insufficiency: a retrospective cross-sectional study. Front Endocrinol (Lausanne). 2024;15:1454802. doi:10.3389/fendo.2024.1454802
Huang, Y., et al. "Using anti-Müllerian hormone to predict premature ovarian insufficiency: a retrospective cross-sectional study." *Frontiers in endocrinology*, vol. 15, 2024, pp. 1454802.
PURPOSE: To evaluate the clinical relevance of serum progesterone levels on the day of frozen embryo transfer (FET) and the dose of vaginal progesterone gel (Crinone) used for early luteal phase suppo...
BACKGROUND: Intrauterine insemination (IUI) is the first line treatment for conditions such as unexplained or mild male factor infertility. Endometrial thickness (EMT) is an important indicator for pr...
INTRODUCTION: The design and functionality of injection devices for controlled ovarian stimulation (COS) significantly influence dose accuracy and patient comfort, affecting adherence and treatment su...